EPS for Agenus Inc. (AGEN) Expected At $-0.28

February 24, 2018 - By Linda Rogers

 EPS for Agenus Inc. (AGEN) Expected At $ 0.28
Investors sentiment increased to 1.34 in Q3 2017. Its up 0.29, from 1.05 in 2017Q2. It increased, as 14 investors sold Agenus Inc. shares while 18 reduced holdings. 15 funds opened positions while 28 raised stakes. 36.96 million shares or 3.93% less from 38.48 million shares in 2017Q2 were reported.
Qvt Lp reported 3.47M shares stake. Zurcher Kantonalbank (Zurich Cantonalbank) reported 0% of its portfolio in Agenus Inc. (NASDAQ:AGEN). Barclays Public Limited Company holds 38,034 shares. Blackrock reported 4.83 million shares stake. State Board Of Administration Of Florida Retirement Sys owns 0% invested in Agenus Inc. (NASDAQ:AGEN) for 21,464 shares. Great West Life Assurance Can has 8,800 shares. Hudson Bay Cap Limited Partnership has 280,000 shares. Schwab Charles Inv Mngmt has invested 0% in Agenus Inc. (NASDAQ:AGEN). First Republic Management Inc owns 22,100 shares for 0% of their portfolio. Ameritas Investment Ptnrs Inc owns 5,577 shares. Meeder Asset Mngmt Inc holds 0% or 454 shares. California Public Employees Retirement System reported 127,253 shares. State Street Corp holds 0% or 1.39M shares. Swiss National Bank holds 0% or 149,200 shares. Crestwood Advsrs Limited Com reported 32,928 shares.

Since October 9, 2017, it had 0 insider purchases, and 5 insider sales for $95,988 activity. The insider Duncan Alex sold $22,651. Buell Jennifer sold $12,152 worth of stock or 3,511 shares. Valentine Karen had sold 8,358 shares worth $28,921 on Monday, October 9. $19,418 worth of Agenus Inc. (NASDAQ:AGEN) was sold by KLASKIN CHRISTINE M on Monday, October 9.

Analysts expect Agenus Inc. (NASDAQ:AGEN) to report $-0.28 EPS on March, 8.They anticipate $0.02 EPS change or 6.67 % from last quarter’s $-0.3 EPS. After having $-0.37 EPS previously, Agenus Inc.’s analysts see -24.32 % EPS growth. The stock increased 4.33% or $0.21 during the last trading session, reaching $5.06. About 2.03M shares traded or 62.99% up from the average. Agenus Inc. (NASDAQ:AGEN) has declined 2.26% since February 24, 2017 and is downtrending. It has underperformed by 18.96% the S&P500.

Agenus Inc. (NASDAQ:AGEN) Ratings Coverage

Among 5 analysts covering Agenus (NASDAQ:AGEN), 4 have Buy rating, 0 Sell and 1 Hold. Therefore 80% are positive. Agenus had 10 analyst reports since July 27, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Thursday, August 3 by Jefferies. As per Friday, March 11, the company rating was upgraded by Maxim Group. The stock has “Buy” rating by Jefferies on Monday, June 26. The company was maintained on Friday, July 29 by Jefferies. The rating was downgraded by Maxim Group to “Hold” on Tuesday, October 27. The stock of Agenus Inc. (NASDAQ:AGEN) has “Neutral” rating given on Friday, October 28 by H.C. Wainwright. As per Thursday, October 27, the company rating was maintained by Maxim Group. The firm has “Buy” rating by Jefferies given on Wednesday, December 16. The firm has “Market Outperform” rating given on Wednesday, March 9 by JMP Securities. The stock of Agenus Inc. (NASDAQ:AGEN) earned “Buy” rating by MLV on Monday, July 27.

Agenus Inc., a clinical-stage immuno-oncology company, focuses on the discovery and development of therapies that engage the body's immune system for patients suffering with cancer. The company has market cap of $515.94 million. The firm offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies; SECANT yeast display, an antibody discovery platform used for the generation of novel monoclonal antibodies; and phage display technologies. It currently has negative earnings. It is also developing checkpoint modulating antibody candidates targeting GITR, OX40, TIM-3, and LAG-3.

More news for Agenus Inc. (NASDAQ:AGEN) were recently published by: Fool.com, which released: “The case for Agenus” on February 13, 2018. Seekingalpha.com‘s article titled: “Agenus: Positioned To Rapidly Enhance Shareholder Value” and published on February 20, 2018 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: